Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA09 in CD19+ Relapsed/Refractory B-cell Hematolymphatic Malignancies
NCT06092047Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Oct 2023
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA09 in B-cell hematologic malignancy, sponsored by PersonGen BioTherapeutics. Primary endpoints: Assessment of the safety after UTAA09 injection treatment at 2 years and Evaluation of the efficacy after UTAA09 injection treatment at 3 months. Started Oct 2023; status: recruiting.
02
Drugs
UTAA09
03
Conditions
B-cell hematologic malignancy
Beyond the preview
Go deeper on NCT06092047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092047.